Role of carvedilol in atrial fibrillation: Insights from clinical trials

American Journal of Cardiology

Volumn 93, Issue 9 SUPPL. 1, 2004, Pages 53-57

  Gheorghiade, Mihai ^a   Robbins, Joel D ^a   Lukas, Mary Ann ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; METOPROLOL; PLACEBO;

CARDIOVERSION; CLINICAL TRIAL; COMORBIDITY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODYNAMICS; HUMAN; INCIDENCE; LONG TERM CARE; PATIENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; SINUS RHYTHM; TOXICITY; UNITED STATES;

EID: 2442709319     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.01.023     Document Type: Article

References (37)

1. American Heart Association. 2004 Heart and Stroke Statistical Update. Available at: http://www.americanheart.org/statistics. Accessed February 11, 2004
2. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN, for the V-HeFT VA Cooperative Studies Group. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: the V-HeFT Studies. Circulation 1993;87:VI102-VI110
3. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ, for the Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341:857-865
4. Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003;4(suppl 7):S21-S30
5. Pardaens K., Van Cleemput J., Vanhaecke J., Fagard R.H. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart. 78:1997;564-568
6. Vigna C., Russo A., De Rito V., Perna G., Villella A., Testa M., Sollazzo V., Fanelli R., Loperfido F. Frequency of left atrial thrombi by transesophageal echocardiography in idiopathic and in ischemic dilated cardiomyopathy. Am J Cardiol. 70:1992;1500-1501
7. Middlekauff H.R., Stevenson W.G., Stevenson L.W. Prognostic significance of atrial fibrillation in advanced heart failure a study of 390 patients. Circulation. 84:1991;40-48
8. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. I. Clinical features of patients at risk. Ann Intern Med 1992;116:1-5
9. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-2150
10. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355
11. Packer M., Colucci W.S., Sackner-Bernstein J.D., Liang C.S., Goldscher D.A., Freeman I., Kukin M.L., Kinhal V., Udelson J.E., Klapholz M., et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure the PRECISE Trial. Circulation. 94:1996;2793-2799
12. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, et al. for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-2806
13. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease: Australia-New Zealand Heart Failure Research Collaborative Group. Circulation 1995;92:212-218
14. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-1390
15. Bergmann CF. Carvedilol plus ACE improved LV remodeling. Today in Cardiology. October 2002
16. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, et al. for the Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13
17. Joglar J.A., Acusta A.P., Shusterman N.H., Ramaswamy K., Kowal R.C., Barbera S.J., Hamdan M.H., Page R.L. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J. 142:2001;498-501
18. Khand A.U., Rankin A.C., Martin W., Taylor J., Gemmell I., Cleland J.G. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 42:2003;1944-1951
19. Meng F., Yoshikawa T., Baba A., Moritani K., Suzuki M., Satoh T., Yokozuka H., Murayama A., Ogawa S. Beta-blockers are effective in congestive heart failure patients with atrial fibrillation. J Card Fail. 9:2003;398-403
20. Merritt J.C., Niebaur M., Tarakji K., Hammer D., Mills R.M. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol. 92:2003;735-736
21. Katritsis D.G., Panagiotakos D.B., Karvouni E., Giazitzoglou E., Korovesis S., Paxinos G., Anagnostopoulos C.E., Camm A.J. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol. 92:2003;1116-1119
22. McMurray J.J., Dargie H.J., Ford I., Sendon J.L., Remme W., Sharpe N., et al. Carvedilol reduces supraventricaular and ventricular arrhythmias after myocardial infarction evidence from the CAPRICORN study. [abstract] Circulation. 104:2001;II-700
23. Eichhorn E.J., Gheorghiade M. Digoxin. Prog Cardiovasc Dis. 44:2002;251-266
24. Farshi R., Kistner D., Sarma J.S., Longmate J.A., Singh B.N. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise a crossover open-label study of five drug regimens. J Am Coll Cardiol. 33:1999;304-310
25. Agarwal A.K., Venugopalan P. Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. Eur J Heart Fail. 3:2001;437-440
26. Heart Failure Society of America. Heart Failure Society of America (HFSA) practice guidelines: HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J Card Fail 1999;5:357-382
27. Grunden J.W., Gilbert E.M., Munger M.A. Augmented digoxin concentrations with carvedilol dosing in mild-moderate heart failure. Am J Ther. 1:1994;157-161
28. Wermeling D.P., Field C.J., Smith D.A., Chandler M.H., Clifton G.D., Boyle D.A. Effects of long-term oral carvedilol on the steady-state pharmacokinetics of oral digoxin in patients with mild to moderate hypertension. Pharmacotherapy. 14:1994;600-606
29. Erdmann E., Lechat P., Verkenne P., Wiemann H. Results from post-hoc analyses of the CIBIS II trial effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail. 3:2001;469-479
30. Lechat P., Hulot J.S., Escolano S., Mallet A., Leizorovicz A., Werhlen-Grandjean M., Pochmalicki G., Dargie H. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 103:2001;1428-1433
31. Wyse DG, for the AFFIRM Investigators. Survival in patients presenting with atrial fibrillation: the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Presented at the 51st Annual Scientific Session for the American College of Cardiology; March 17-20, 2002; Atlanta, Georgia. Presentation 405-1. Available at: http://www.acc.org/2002ann_meeting/ abstract_02.htm
32. Van Den Berg M.P., Tuinenburg A.E., van Veldhuisen D.J., de Kam P.J., Crijns H.J. Cardioversion of atrial fibrillation in the setting of mild to moderate heart failure. Int J Cardiol. 63:1998;63-70
33. Lehto M., Kala R. Persistent atrial fibrillation a population based study of patients with their first cardioversion. Int J Cardiol. 92:2003;145-150
34. Zarowitz B.J., Gheorghiade M. Optimal heart rate control for patients with chronic atrial fibrillation are pharmacologic choices truly changing? Am Heart J. 123:1992;1401-1403
35. Korantzopoulos P., Kolettis T., Siogas K., Goudevenos J. Atrial fibrillation and electrical remodeling the potential role of inflammation and oxidative stress. Med Sci Monit. 9:2003;RA225-RA229
36. Arumanayagam M., Chan S., Tong S., Sanderson J.E. Antioxidant properties of carvedilol and metoprolol in heart failure a double-blind randomized controlled trial. J Cardiovasc Pharmacol. 37:2001;48-54
37. McNamara R.L., Tamariz L.J., Segal J.B., Bass E.B. Management of atrial fibrillation review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med. 139:2003;1018-1033